Biocytogen-B Shares Extend Rally with Over 6% Gain on AI-Driven Obesity Drug Partnership

Stock News04-02

Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic collaboration agreement with SIHUAN PHARM. The partnership will leverage Biocytogen's leading fully human antibody development platform and SIHUAN PHARM's extensive experience in drug development, production, and commercialization. The companies will collaborate on innovative drug research in multiple disease areas, including weight loss, aiming to combine strengths and resources for a long-term, stable relationship. The first project under this agreement will focus on SIHUAN PHARM's next-generation weight-loss drug candidate. SIHUAN PHARM has expressed strong confidence in Biocytogen's technological capabilities. Biocytogen will contribute its self-developed model animal and efficacy platforms, fully human antibody discovery platform, and AI-powered antibody drug development platform to support the collaboration. By integrating both parties' capabilities in innovation and industrial application, the partnership is expected to enhance the efficiency of innovative drug development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141444588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141444588","market":"us","top_or_hot":-1,"title":"Biocytogen-B Shares Extend Rally with Over 6% Gain on AI-Driven Obesity Drug Partnership","media":"Stock News","content":"<p>Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic collaboration agreement with SIHUAN PHARM. The partnership will leverage Biocytogen's leading fully human antibody development platform and SIHUAN PHARM's extensive experience in drug development, production, and commercialization. The companies will collaborate on innovative drug research in multiple disease areas, including weight loss, aiming to combine strengths and resources for a long-term, stable relationship. The first project under this agreement will focus on SIHUAN PHARM's next-generation weight-loss drug candidate. SIHUAN PHARM has expressed strong confidence in Biocytogen's technological capabilities. Biocytogen will contribute its self-developed model animal and efficacy platforms, fully human antibody discovery platform, and AI-powered antibody drug development platform to support the collaboration. By integrating both parties' capabilities in innovation and industrial application, the partnership is expected to enhance the efficiency of innovative drug development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen-B Shares Extend Rally with Over 6% Gain on AI-Driven Obesity Drug Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen-B Shares Extend Rally with Over 6% Gain on AI-Driven Obesity Drug Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-02 11:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic collaboration agreement with SIHUAN PHARM. The partnership will leverage Biocytogen's leading fully human antibody development platform and SIHUAN PHARM's extensive experience in drug development, production, and commercialization. The companies will collaborate on innovative drug research in multiple disease areas, including weight loss, aiming to combine strengths and resources for a long-term, stable relationship. The first project under this agreement will focus on SIHUAN PHARM's next-generation weight-loss drug candidate. SIHUAN PHARM has expressed strong confidence in Biocytogen's technological capabilities. Biocytogen will contribute its self-developed model animal and efficacy platforms, fully human antibody discovery platform, and AI-powered antibody drug development platform to support the collaboration. By integrating both parties' capabilities in innovation and industrial application, the partnership is expected to enhance the efficiency of innovative drug development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"","article_id":"1141444588","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141444588","pubTimestamp":1775100980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","688796":"百奥赛图","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","00460":"四环医药","BK4588":"碎股","BK1191":"制药","BK1515":"抗疫概念","AGIX":"通用人工智能 ETF-AGIX","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","AIPO":"Defiance AI and Power Infrastructure ETF","BK1574":"生物医药B类股","BK0216":"研究试验","BK1593":"医美概念股","06978":"永泰生物-B","02315":"百奥赛图-B","BK1161":"生物科技","BK1600":"工业大麻"},"translate_title":"Biocytogen-B股价延续涨势，人工智能驱动的肥胖药物合作伙伴关系上涨超过6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688796":1,"02315":1,"CHAT":1,"AIPO":1,"AGIX":1,"06978":1,"VXUS":1,"00460":1},"content_text":"Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic collaboration agreement with SIHUAN PHARM. The partnership will leverage Biocytogen's leading fully human antibody development platform and SIHUAN PHARM's extensive experience in drug development, production, and commercialization. The companies will collaborate on innovative drug research in multiple disease areas, including weight loss, aiming to combine strengths and resources for a long-term, stable relationship. The first project under this agreement will focus on SIHUAN PHARM's next-generation weight-loss drug candidate. SIHUAN PHARM has expressed strong confidence in Biocytogen's technological capabilities. Biocytogen will contribute its self-developed model animal and efficacy platforms, fully human antibody discovery platform, and AI-powered antibody drug development platform to support the collaboration. By integrating both parties' capabilities in innovation and industrial application, the partnership is expected to enhance the efficiency of innovative drug development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141444588","isCrawlerRequest":true}